Outcomes in COVID-19 bebtelovimab studies
Outcomes in bebtelovimab studies.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BQ.1.1 [Planas ] . Monoclonal antibody use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape
[Choudhary ] .
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -151%
2.51 [0.10-61.1]
death
1/252
0/128
Improvement, RR [CI] Treatment Control Dryden-Peterson 86%
0.14 [0.01-2.76]
death
0/377
3/377
Tau​2 ​ = 1.64, I​2 ​ = 39.9%, p = 0.7
Early treatment 44%
0.56 [0.03-9.27]
1/629
3/505
44% improvement All studies 44%
0.56 [0.03-9.27]
1/629
3/505
44% improvement 2 bebtelovimab COVID-19 studies c19 early.org/bt Dec 2022Tau​2 ​ = 1.64, I​2 ​ = 39.9%, p = 0.7
Effect extraction pre-specified (most serious outcome) Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -151%
2.51 [0.10-61.1]
1/252
0/128
Improvement, RR [CI] Treatment Control Dryden-Peterson 86%
0.14 [0.01-2.76]
0/377
3/377
Tau​2 ​ = 1.64, I​2 ​ = 39.9%, p = 0.7
Early treatment 44%
0.56 [0.03-9.27]
1/629
3/505
44% improvement All studies 44%
0.56 [0.03-9.27]
1/629
3/505
44% improvement 2 bebtelovimab COVID-19 mortality results c19 early.org/bt Dec 2022Tau​2 ​ = 1.64, I​2 ​ = 39.9%, p = 0.7
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -27%
1.27 [0.25-6.46]
hosp.
5/252
2/128
Improvement, RR [CI] Treatment Control Dryden-Peterson 29%
0.71 [0.32-1.59]
hosp.
10/377
14/377
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.55
Early treatment 20%
0.80 [0.39-1.64]
15/629
16/505
20% improvement All studies 20%
0.80 [0.39-1.64]
15/629
16/505
20% improvement 2 bebtelovimab COVID-19 hospitalization results c19 early.org/bt Dec 2022Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.55
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -151%
2.51 [0.10-61.1]
death
1/252
0/128
Improvement, RR [CI] Treatment Control Dryden-Peterson 86%
0.14 [0.01-2.76]
death
0/377
3/377
Tau​2 ​ = 1.64, I​2 ​ = 39.9%, p = 0.7
Early treatment 44%
0.56 [0.03-9.27]
1/629
3/505
44% improvement All studies 44%
0.56 [0.03-9.27]
1/629
3/505
44% improvement 2 bebtelovimab COVID-19 serious outcomes c19 early.org/bt Dec 2022Tau​2 ​ = 1.64, I​2 ​ = 39.9%, p = 0.7
Effect extraction pre-specified (most serious outcome) Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) 36%
0.64 [0.40-1.03]
viral+
33/252
26/128
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.066
Early treatment 36%
0.64 [0.40-1.03]
33/252
26/128
36% improvement All studies 36%
0.64 [0.40-1.03]
33/252
26/128
36% improvement 1 bebtelovimab COVID-19 viral clearance result c19 early.org/bt Dec 2022Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.066
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -151%
2.51 [0.10-61.1]
death
1/252
0/128
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.58
Early treatment -151%
2.51 [0.10-61.1]
1/252
0/128
-151% improvement All studies -151%
2.51 [0.10-61.1]
1/252
0/128
-151% improvement 1 bebtelovimab COVID-19 Randomized Controlled Trials c19 early.org/bt Dec 2022Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.58
Effect extraction pre-specified (most serious outcome) Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -151%
2.51 [0.10-61.1]
1/252
0/128
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.58
Early treatment -151%
2.51 [0.10-61.1]
1/252
0/128
-151% improvement All studies -151%
2.51 [0.10-61.1]
1/252
0/128
-151% improvement 1 bebtelovimab COVID-19 RCT mortality result c19 early.org/bt Dec 2022Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.58
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Dryden-Peterson 86%
0.14 [0.01-2.76]
death
0/377
3/377
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.2
Early treatment 86%
0.14 [0.01-2.76]
0/377
3/377
86% improvement All studies 86%
0.14 [0.01-2.76]
0/377
3/377
86% improvement 1 bebtelovimab COVID-19 peer reviewed studies c19 early.org/bt Dec 2022Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.2
Effect extraction pre-specified (most serious outcome) Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -151%
2.51 [0.10-61.1]
death
1/252
0/128
Improvement, RR [CI] Treatment Control Lilly (RCT) -201%
3.01 [0.12-73.2]
death
1/127
0/128
Lilly (RCT) -27%
1.27 [0.25-6.46]
hosp.
5/252
2/128
Lilly (RCT) -51%
1.51 [0.26-8.90]
hosp.
3/127
2/128
Lilly (RCT) -2%
1.02 [0.15-7.16]
hosp.
2/125
2/128
Lilly (RCT) 36%
0.64 [0.40-1.03]
viral+
33/252
26/128
Lilly (RCT) 38%
0.62 [0.35-1.10]
viral+
16/127
26/128
Lilly (RCT) 33%
0.67 [0.38-1.17]
viral+
17/125
26/128
Dryden-Peterson 86%
0.14 [0.01-2.76]
death
0/377
3/377
Dryden-Peterson 43%
0.57 [0.28-1.19]
death/hosp.
10/377
17/377
Dryden-Peterson 29%
0.71 [0.32-1.59]
hosp.
10/377
14/377
Bebtelovimab COVID-19 outcomes c19 early.org/bt Dec 2022Favors bebtelovimab
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
